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Special Topics
1135-69 Impact of Gender on Outcome Following Percutaneous 
Coronary Intervention
John H. Chiu, Deepak L. Bhatt, Khaled M. Ziada, Stephen G. Ellis, The Cleveland Clinic 
Foundation, Cleveland, OH
Background: Prior reports have suggested that women have increased mortality com-
pared to men following percutaneous coronary intervention (PCI). We examined the
characteristics and outcomes of women and men undergoing PCI over the past decade.
Methods: In this analysis, we studied 18,039 patients undergoing PCI at The Cleveland
Clinic Foundation from 1992 to 2002. Mean follow-up duration was 4.8 years.
Results: Twenty-nine percent (n=5301) of the patients were female. Compared to the
cohort of males, the female cohort was older (mean age 67 vs. 62 years) and had a
greater prevalence of diabetes mellitus (34% vs. 24%), hypertension (71% vs. 58%), and
peripheral vascular disease (9% vs. 7%); all p<0.0001. The mean left ventricular ejection
fraction was slightly higher in the female group (54% vs. 52%, p<0.0001). There was no
significant difference in baseline prevalence of renal insufficiency. Women were more
likely to present with acute myocardial infarction (MI) (9% vs. 7%, p=0.0008) or unstable
angina (67% vs. 58%, p<0.0001). Procedural success rates were similar in both genders,
but the female cohort had a greater incidence of blood product transfusion (12% vs. 4%,
p<0.0001) and hematoma (5% vs. 2%, p<0.0001) following PCI. The rate of MI at 1 year
was slightly higher among females (10% vs. 9%, p=0.0035), though revascularization
rates at 1 year were not significantly different between genders. One-year mortality was
higher in the female cohort (7% vs. 5%, p<0.0001). After adjustment in a multivariate
model, the Cox proportional hazard ratio for mortality in females was 1.01 (95% CI 0.93
to 1.11, p=0.78). The hazard ratio for the combined endpoint of death or MI was 1.05
(95% CI 0.97 to 1.13, p=0.23).
Conclusions: There is a greater incidence of post-procedural bleeding complications
among women. After adjustment in a multivariate model, the risk for long-term mortality
is not significantly different between genders following PCI.
1135-70 Gender Differences in Initial Diagnosis of Coronary 
Heart Disease
Barbara P. Yawn, Peter Wollan, Steven Jacobsen, Veronique Roger, Olmsted Medical 
Center, Rochester, MN, Mayo Clinic, Rochester, MN
Background: Much research exists on the evaluation and treatment of coronary heart
disease (CHD) following initial presentation for chest pain or myocardial infarction (MI).
Yet, little is known about evaluation of possible CHD preceding first MI and how it may dif-
fer in women and men. Methods: To determine and compare the timing of first CHD
diagnosis and CHD risk factor identification and treatment in men and women prior to
their first MI using a community population cohort of Olmsted County, Minnesota resi-
dents. All MIs were validated by standardized criteria. Using the Rochester Epidemiology
Project, records of all health care providers in Olmsted County were reviewed and data
were collected for the 10 years prior to incident MI. Primary endpoints were the date of
first CHD diagnosis documented in the medical records and the dates of evaluation and
treatment of CHD risk factors. Results: Data on pre-MI care were available for an aver-
age of 8.7 years for the 298 subjects (150 women and 148 men). Average age at incident
MI was 74.7 years for women and 65.9 years for men (p<0.0001). About half of the
women (52.1%), but only 30.24% of the men had a diagnosis of CHD prior to their first MI
(p<0.01). For those having a CHD diagnosis prior to first MI, the average time between
first CHD diagnosis and MI was 5.1 years and not different for men and women. Family
history of CHD, blood lipids, and blood pressure were assessed in 88% to 100% of all
men and women (pairwise p>0.05). Only assessment of blood glucose was different in
men and women (66.9% of men vs. 88.0% of women (p=0.05). Treatment rates of identi-
fied risk factors did not differ by gender. Recognition of CHD and risk factor assessment
prior to first MI increased with age. Conclusions: Men were less likely than women to
have a diagnosis of CHD but similar rates of risk factor evaluation prior to their first MI.
This may be explained by the later age at which women experience their first AMI
(greater time for CDH recognition), delayed care seeking in the men or gender-related
patterns of disease presentation (fewer prodromal symptoms in men). Irrespective of the
reason, the results suggest less opportunity for CHD specific intervention in men prior to
their first MI.
1135-71 Hormone Replacement Therapy and Cardiac Disease: A 
Challenge to Change Practice Patterns
Cheryl A. Gibson, James L. Vacek, Kelly Hattabaugh, Jennifer Staley, University of 
Kansas School of Medicine, Kansas City, KS
Background. Historically, hormone replacement therapy (HRT) has been an essential
element in the management of postmenopausal women. Physicians are now re-examin-
ing treatment options after a major placebo-controlled primary prevention trial of the risks
and benefits of combined estrogen and progestin therapy, a component of the Women’s
Health Initiative, was prematurely halted. Given the lack of evidence from randomized
clinical trials supporting HRT’s benefit beyond that of managing traditional menopausal
symptoms, the objective of this study was to examine the characteristics of patients tak-
ing HRT in a large cardiology practice. Method. Of 73,969 female patients, 7,279 (10%)
women (age 65 ± 11 yrs) are current HRT users undergoing treatment with conventional
doses of conjugated equine estrogens with or without medroxyprogesterone acetate.
Results. The mean length of time on HRT was 38 ± 23 months. An assessment of
chronic disease status indicated that significantly more women on HRT had a diagnosis
of hypertension, hypercholesterolemia, diabetes, or congestive heart failure (all p’s <
0.001). Compared to women not taking HRT, women on HRT were more likely to be tak-
ing ACE inhibitors (OR= 6.63; 95% CI 6.15-7.14), lipid-lowering medications (OR= 9.54;
95% CI = 8.93 – 10.19), aspirin (OR= 10.10; 95% CI 9.48 –10.76), and beta blockers
(OR= 7.40; 95% CI 6.93 – 7.91). We examined contraindications to HRT including smok-
ing status and the presence of breast cancer, uterine bleeding, or deep vein thrombosis.
Women on HRT were 6.2 times more likely to be smokers (OR=6.18; 95% CI 5.50-6.94).
Conclusions. Accordingly, HRT use in a potentially high-risk population is frequent,
although aggressive medical therapy is concomitantly utilized. Active interventions to
change HRT prescribing practices may be appropriate.
1135-72 Higher Mortality and Less Evidence-Based Therapies 
Among Medicaid-Insured Patients With High-Risk Acute 
Coronary Syndromes: Results From CRUSADE
James E. Calvin, Matthew T. Roe, Anita Chen, Gerard X. Brogan, Jr., Elizabeth R. 
DeLong, W. Brian Gibler, E. Magnus Ohman, Dan Fintel, Sidney C. Smith, Jr., Eric D. 
Peterson, Rush-Presbyterian-St.Luke's Medical Center, Chicago, IL, Duke Clinical 
Research Institute, Durham, NC
Background: A recent Institute of Medicine report emphasizes that the healthcare sys-
tem should aim to provide equitable and evidence-based care for all. The extent to which
insurance coverage affects the care and outcomes of patients with non–ST-elevation
acute coronary syndromes (NSTE ACS) is unknown.
Methods: We evaluated 16,755 patients aged <65 years with NSTE ACS (positive car-
diac markers or ischemic ST-segment changes) treated at 292 US hospitals participating
in the CRUSADE Initiative. We compared treatment and outcomes of Medicaid patients
with non-Medicaid (HMO, private insurance, and self-insured) patients after adjusting for
demographics, clinical factors, hospital features, and access to cardiology care.
Results: Medicaid patients were slightly older than non-Medicaid patients, and more
were female (38% vs. 28%, p<.0001) and African-American (25% vs. 12%, p<.0001).
Medicaid patients were less likely to be treated by a cardiologist (65% vs. 71%, p<0.001)
and received fewer evidence-based treatments and procedures (Table). In-hospital mor-
tality was nearly 50% higher in Medicaid patients, even after risk adjustment.
Conclusions: Medicaid patients younger than 65 admitted with NSTE ACS are less
likely to receive evidence-based therapies and interventions and have significantly higher
in-hospital mortality rates than those with other forms of insurance. The reasons for these
inequities need to be explored. 
* For comparing Medicaid patients to non-Medicaid patients.
Rates of Cardiac Procedures after AMI
1993 1994 1995 1996 1997 1998 1999
Unadjusted
CATH Men 47.1 49.5 52.1 53.4 53.4 54.6 55.4
CATH Women 35.3 37.2 40.1 41.3 41.8 42.6 43.3
PCI Men 17.1 19.0 20.6 21.2 21.8 24.7 26.0
PCI Women 13.9 15.3 16.8 17.2 18.3 20.0 21.0
CABG Men 15.1 15.9 17.3 17.5 17.3 16.3 16.3
CABG Women 9.4 9.8 10.9 11.2 10.9 10.2 9.8
REVASC Men 31.1 33.7 36.7 37.6 38.1 40.1 41.3
REVASC Women 22.5 24.3 26.8 27.6 28.4 29.6 30.2
Adjusted
CATH Men 42.2 44.2 46.3 48.2 49.2 51.3 53.3
CATH Women 36.6 38.5 41.4 43.4 45.1 47.3 49.5
PCI Men 14.7 16.3 17.6 18.6 19.7 23.1 25.2
PCI Women 14.0 15.4 17.0 17.9 19.6 22.4 24.6
CABG Men 13.4 14.1 15.4 15.9 16.0 15.5 15.8
CABG Women 9.8 10.3 11.4 11.9 11.9 11.5 11.4
REVASC Men 27.1 29.4 32.2 33.4 34.8 37.7 39.9
REVASC Women 22.9 24.9 27.4 28.9 30.7 33.2 35.1
Medicaid
(n=3,549)
Non-Medicaid
(n=13,106)
Adjusted OR *
(95% CI)
Acute Treatments
Aspirin < 24 hrs 90% 94% 0.78 (0.68-0.90)
B-Blocker < 24 hrs 76% 81% 0.86 (0.77-0.95)
Heparin < 24 hrs 81% 87% 0.80 (0.72-0.89)
GP IIb-IIIa < 24 hrs 36% 49% 0.84 (0.76-0.94)
Cardiac Cath < 48 hrs 48% 67% 0.72 (0.66-0.79)
PCI < 48 hrs 27% 42% 0.78 (0.72-0.86)
Discharge Medications
Clopidogrel 52% 62% 0.87 (0.80-0.95)
B-Blocker 81% 85% 0.86 (0.75-0.99)
Statin 61% 71% 0.78 (0.71-0.85)
Outcomes
Death 3.3% 1.2% 1.46 (1.10-1.93)
Reinfarction 3.0% 2.5% 1.05 (0.83-1.33)
